Trials / Completed
CompletedNCT02262975
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 532 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 50 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
This study is an observational study conducted prospectively under routine clinical setting for 1 year with about 700 patients diagnosed as Alzheimer's disease who will be treated by donepezil (Aricept) as monotherapy. The subjects will be recruited in the selected institutions of about 8 countries in Asia.
Detailed description
Participation in this study places no additional visit schedule, which will be determined by the investigator's judgment based on the disease progression of each subject. Investigators educate subjects to keep decided visit schedule, and collect the required information for case record from (CRF) on the visit.
Conditions
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2014-10-13
- Last updated
- 2016-12-28
Locations
26 sites across 6 countries: China, Philippines, Singapore, South Korea, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT02262975. Inclusion in this directory is not an endorsement.